Autoantibodies to insulin are a harbinger of autoimmunity in type 1 diabetes in humans and in non-obese diabetic mice. To understand the genesis of these autoantibodies, we investigated the interactions of insulin-specific T and B lymphocytes using T cell and B cell receptor transgenic mice. We found spontaneous anti-insulin germinal center (GC) formation throughout lymphoid tissues with GC B cells binding insulin. Moreover, because of the nature of the insulin epitope recognized by the T cells, it was evident that GC B cells presented a broader repertoire of insulin epitopes. Such broader recognition was reproduced by activating naive B cells ex vivo with a combination of CD40 ligand and interleukin 4. Thus, insulin immunoreactivity extends beyond the pancreatic lymph node–islets of Langerhans axis and indicates that circulating insulin, despite its very low levels, can have an influence on diabetogenesis.
In humans and non-obese diabetic (NOD) mice, insulin autoreactivity is a prominent feature during the initiation and progression of type 1 diabetes (T1D; Nakayama et al., 2005; Zhang et al., 2008; Mohan et al., 2010; Unanue, 2014). Insulin autoantibodies (IAAs) are used as important predictive biomarkers for disease susceptibility and prognosis (Zhang and Eisenbarth, 2011). Although IAAs can be of the IgM or IgG class (Bodansky et al., 1986; Dean et al., 1986), IgG IAAs are associated with robust diabetes progression (Achenbach et al., 2004; Hoppu et al., 2004). These findings point to an essential role of CD4 T helper cells in supporting generation of class-switched IAAs through cognate interactions with anti-insulin B cells. However, issues concerning the source of T cell help, the nature of the T cell–B cell interaction, and the sites of IAA production remain largely unexplained.
In this study, we have examined the interactions between insulin-reactive T and B cells in NOD mice with a goal of identifying the nature and sites of T cell–B cell interactions and their consequences. We previously identified CD4 T cells to insulin that escaped thymic negative selection, entered islets of Langerhans, and caused diabetes, of which the 8F10 T cell, used here as a TCR transgenic mouse, is representative (Mohan et al., 2013). The 8F10 mice had IAAs in relatively high titers directed to conformational insulin, but these T cells specifically recognize the 12–20 sequence of the insulin B chain (B:12-20), an epitope that is not presented from the processing of insulin (Mohan et al., 2011, 2013). Insulin processing by APCs, including B cells, generates a close but distinct sequence; that is, from 13–21 (B:13-21), a one–amino acid shift in the MHC-binding register (Mohan et al., 2011). However, the B:12-20 epitope is presented in islets from secretory granules containing catabolites of insulin that are transferred to intra-islet resident APCs (Mohan et al., 2010; Vomund et al., 2015). Studying this CD4 T cell is important for two reasons. First, because a majority of the insulin-reactive T cells recognize the B:12-20 epitope (Mohan et al., 2010, 2011), it remains to be defined how this T cell can interact with anti-insulin B cells and support IAA production when B cells that take up insulin should not present it. Second, it considers where the interaction is taking place; that is, whether insulin presentation is restricted to the pancreatic LNs (pLNs) or extended to other peripheral sites. The present view is that the pLN that drains the islets is a key site for the autoimmune process to move forward (Höglund et al., 1999; Gagnerault et al., 2002; Levisetti et al., 2004). Insulin circulates at low picomolar levels, an amount that is most likely below a threshold for effective T cell–B cell interactions outside the islet–pLN axis. But, notably, endogenous insulin has been shown to have an effect in modulating immature anti-insulin B cells in the bone marrow (Henry et al., 2009; Henry-Bonami et al., 2013) and mature B cells in the spleen (Rojas et al., 2001; Acevedo-Suárez et al., 2005).
Examining anti-insulin T cell–B cell interaction is hindered by the difficulty of tracking the insulin specificity in the polyclonal BCR repertoire. This limitation can be overcome by the VH125.NOD anti-insulin BCR heavy chain transgenic model developed by one of us (Rojas et al., 2001). The VH125 BCR heavy chain pairs with various endogenous light chains, giving rise to 1–3% insulin-specific B cells of the repertoire (Hulbert et al., 2001; Henry-Bonami et al., 2013). A recent study directly targeted the rearranged VH125 variable region genes into the endogenous IgH locus (Williams et al., 2015). Consequently, the anti-insulin B cells formed in the resulting VH125SD mice are capable of class-switch recombination, permitting assessment of the IgG class of IAAs.
In this study, the 8F10 and VH125SD mouse strains were crossed and examined. The 8F10 T cells provided help to anti-insulin B cells, leading to germinal center (GC) formation and IAA production. The T cell–B cell interaction took place because activated GC B cells acquired altered insulin processing, resulting in presentation of the B:12-20 epitope to 8F10 T cells. Furthermore, insulin-specific GC formation was observed in multiple LNs and spleens, most likely resulting from the low level of insulin in the blood or lymph.
Two approaches to study the interactions between insulin-specific CD4 T cells and B cells
Insulin-specific T cell–B cell interactions were examined in two complementary models. In one, we crossed 8F10 TCR transgenic mice with the VH125SD.NOD BCR transgenic mice. In this model, the pathogenicity of 8F10 T cells was suppressed by strong regulatory mechanisms that prevented spontaneous diabetes. Our previous study showed that the 8F10 mice developed diabetes only when crossed onto the Rag1−/− background that excludes TCR α-chain rearrangement and T regulatory cell (T reg cell) development (Mohan et al., 2013). As shown in Fig. 1 A, none of the female 8F10-VH125SD mice developed diabetes, whereas the nontransgenic (Tg−/−) littermates did. Indeed, experiments in progress indicate that treatment of these mice with anti-CD25 (PC61) antibody resulted in diabetes development in three out of five mice, whereas no mice under the isotype control antibody treatment became diabetic (Fig. 1 B).
At 8 wk of age, the islets of the 8F10-VH125SD mice displayed a heterogeneous profile of inflammation, as manifested by coexistence of peri-insulitic and mild intra-insulitic lesions (Fig. 1, C and D). Flow cytometry analyses revealed a significantly lower frequency of CD45+ leukocytes infiltrating the islets of 8F10-VH125SD mice relative to Tg−/− littermates (Fig. 1 E). Furthermore, infiltration of CD103+ DCs, a process required for diabetes development (Ferris et al., 2014), was also limited in the double transgenic mice (Fig. 1 F). Infiltration by the B220+ B cells was significantly less in the 8F10-VH125SD than the Tg−/− littermates (Fig. 1 G). FoxP3+ T reg cells were found in the pLN, and more strikingly, a significantly higher number of CD4+ T cells in the islets of the 8F10-VH125SD mice were FoxP3 positive (Fig. 1 H).
The second model consisted of transferring naive T cells (CD4+CD8−B220−CD25−CD62LhiCD44−) isolated from 8F10.Rag1−/− mice and B cells (CD19+CD4−CD8−IgMa+GL7−IgG−) from the VH125SD mice into NOD.Rag1−/− recipients. Under this approach, diabetes developed. Transfer of VH125SD B cells did not induce diabetes during a 50-d monitoring period (Fig. 2 A). Transfer of 8F10.Rag1−/− T cells alone or together with B cells from conventional NOD mice induced diabetes with a similar kinetics (Fig. 2 A). Conventional NOD B cells did not exacerbate diabetes transfer, possibly because of a low number of anti-insulin B cells in the repertoire. Indeed, B cells from the VH125SD mice significantly enhanced the ability of 8F10.Rag1−/− T cells to drive diabetes (Fig. 2 A). These results indicate the importance of anti-insulin T cell–B cell cooperation in promoting diabetes development, in agreement with previous studies showing the capacity of the VH125 BCR in exacerbating diabetes (Hulbert et al., 2001).
IAA production in the two models
The sera of the 8F10-VH125SD mice contained the highest titers of IAAs across the IgG1, IgG2a, and IgG2b subclasses relative to the 8F10, VH125SD, and Tg−/− littermates (Fig. 2 B, left). Low levels of IAAs with each IgG subclass were found in the Tg−/− and VH125SD mice (Fig. 2 B, left). Most of the IAAs in the 8F10 mice were IgG1, with some moderate levels of IgG2b (Fig. 2 B, left). Importantly, the IAAs were blocked by excess free insulin, indicating their specificity to conformational insulin (Fig. 2 B, right). Antibodies to denatured insulin or free 9–23 peptide were not detected (not depicted). Thus, 8F10 T cells promote production of class-switched IAAs recognizing native insulin.
In the second model of NOD.Rag1−/− mice transferred with 8F10.Rag1−/− T cells plus VH125SD B cells, diabetes developed with concomitant IAA production encompassing IgG1, IgG2a, and IgG2b subclasses (Fig. 2 C). These mice had significantly higher titers of IAAs than NOD.Rag1−/− recipients of 8F10.Rag1−/− T cells alone or 8F10.Rag1−/− T cells plus WT B cells (Fig. 2 C). The IAAs specifically recognized native insulin as indicated by their inhibition with free insulin (Fig. 2 C). Of note, the non–insulin-reactive BDC2.5 T cells, when cotransferred with VH125SD B cells, did not induce IAA production (Fig. 2 C). Thus, in the T cell–B cell cotransfer model, IAAs originate from specific anti-insulin T cell–B cell interactions that promote diabetes progression.
GC B cells in the presence of 8F10 T cells
The high titer of class-switched IAAs in the 8F10-VH125SD mice indicates active insulin-specific GC responses. We examined the B cells from the pLN for their reactivity to insulin by flow cytometry. The GC (GC+) B cells were defined as CD19+FashiIgDloGL7+ and the non-GC (GC−) B cells as CD19+FasloIgDhiGL7− (Fig. 3 A). Insulin-specific B cells were identified by their binding to biotinylated insulin in the presence or absence of a 10-fold excess of unlabeled insulin.
Strikingly, 45% of the GC+ B cells in the pLNs of the 8F10-VH125SD mice bound insulin, and the binding was completely blocked by excess soluble insulin (Fig. 3 B, right). The non-GC insulin-binding B cells were few in the 8F10-VH125SD (2.8%) mice, consisting of two sets distinguished by the mean fluorescence intensities of the biotinylated insulin staining (Fig. 3 C, top). This is likely because the VH125SD BCR heavy chain pairs randomly with endogenous light chains, giving rise to BCRs with different affinities to insulin (Henry et al., 2010; Henry-Bonami et al., 2013). In contrast, very few B cells in the GCs of the 8F10 (0.1%) and VH125SD (0.3%) mice bound insulin (Fig. 3 B). Quantification of multiple experiments showed that the frequency of the insulin-binding B cells in the GCs of the 8F10-VH125SD mice was significantly higher than the 8F10 and VH125SD mice, whereas the GC− insulin-binding B cells were comparable between the 8F10-VH125SD and VH125SD mice (Fig. 3 D). Thus, anti-insulin B cells are specifically selected into GCs from a polyclonal repertoire, where in the presence of 8F10 T helper cells, they underwent a 10–30-fold expansion, correlating with the high titers of IAAs.
Systemic generation of anti-insulin GCs
We next examined such insulin-specific GC formation in other lymphoid organs and found that the mesenteric LNs (mLNs), inguinal (iLNs), and axillary LNs (aLNs) contained 20–50% of insulin-binding B cells (Fig. 4 A, top). The frequency of the insulin-binding B cells in the GCs of the mLN, iLN, and aLN was comparable with pLN (Fig. 4 B). The GCs in the spleen had a moderate number (12%) of insulin-binding B cells (Fig. 4 A, top). In contrast, anti-insulin B cells only constituted a small fraction (≤3%) of the GC− B cells in all of the lymphoid organs (Fig. 4 A, bottom). Therefore, the development of insulin-specific GCs was systemic, indicating that the very low level of insulin in blood or lymph (Rasio et al., 1967; Yang et al., 1989) must serve as the source of the GC B cell responses.
To evaluate class-switch recombination, we assessed surface IgMa and IgG expression on the GC+ anti-insulin (GC+INS+) B cells as well as the non-GC B cells with high and low insulin-binding mean fluorescence intensities (designated as GC−INShi and GC−INSlo, respectively; gated according to Fig. 4 C). Strikingly, class-switched (IgG+IgMa−) B cells (24–45%) were only found in the GC+INS+ B cell subset in all the lymphoid sites (Fig. 4 D, top), whereas the GC−INSlo and GC−INShi B cells had very few IgG-bearing B cells (1.1–2.7% and 0.4–1%, respectively), and >80% remained IgMa+IgG− (Fig. 4 D, middle and bottom). In addition, many of the IgG-negative GC+INS+ B cells (42–59%) had decreased surface IgMa expression (IgMalo), perhaps representing B cells initiating class-switch recombination (Fig. 4 D, top). This IgG−IgMalo population was largely absent in the GC−INSlo (3.1–4.2%) and GC−INShi (0.3–1.2%) subsets (Fig. 4 D, middle and bottom). Thus, anti-insulin B cells that differentiated into the GC stage are competent to class switch, correlating with the various IgG subclasses of IAAs.
The finding of systemic anti-insulin GC formation was also observed in NOD.Rag1−/− recipients of 8F10.Rag1−/− T cells plus VH125SD B cells. Specifically, GC responses were found in the pLN, mLN, and spleen of these mice on day 20 after transfer (Fig. 4 E). More importantly, the GL7+ B cells were exclusively insulin specific, further confirming that only anti-insulin B cells can be selected into GCs by the 8F10.Rag1−/− T cells. When naive BDC2.5 T cells were transferred with VH125SD B cells, they triggered GC reactions only in the pLN, but none of the GL7+ B cells bound insulin (Fig. 4 E). These results confirm that 8F10 T cells directly help insulin-specific B cells to form GCs by using native insulin presented in multiple lymphoid organs.
8F10 T cells differentiate into functional T follicular helper cells (Tfh cells)
Corresponding with the systemic anti-insulin GC responses, development of Tfh cells was found in various LNs of the 8F10-VH125SD mice (Fig. 5). This was evident by finding CD4 T cells expressing CXCR5 and PD-1, a feature indicating Tfh lineage commitment (Fig. 5 A). RT-PCR analyses revealed that FACS-sorted Tfh cells but not naive T cells expressed genes encoding CXCR5 (cxcr5), PD-1 (pdcd1), and Bcl-6 (bcl6; Fig. 5 B, top). The Tfh cells also highly expressed genes encoding CD40 ligand (cd40lg), IL-4 (il4), and IFN-γ (ifng; Fig. 5 B, bottom). In the transfer model, naive 8F10.Rag1−/− T cells differentiated into CXCR5hiPD-1hi Tfh cells in the pLNs, mLNs, and spleen when cotransferred with VH125SD B cells (Fig. 5 C). Collectively, these results suggest that 8F10 T cells differentiate into committed Tfh cells capable of providing key mediators shaping GC responses and antibody isotypes (Garside et al., 1998; Takahashi et al., 1998; Reinhardt et al., 2009; Crotty, 2011; Victora and Nussenzweig, 2012).
Insulin-specific GC B cells have altered insulin processing and presentation pathways
8F10 T cells specifically recognize the B:12-20 epitope that binds weakly to I-Ag7. This peptide segment is edited off when insulin is processed by APCs (Mohan et al., 2011). The findings that 8F10 T cells sustain GC B cell responses and promote conformation-specific antibodies raised a conundrum. It suggested that GC B cells may have altered insulin-processing mechanisms that allow presentation of the 12–20 epitope to 8F10 T cells.
FACS-sorted GC+INS+ cells from the 8F10-VH125SD mice were tested for presentation of insulin epitopes. In parallel, the GC−INSlo and GC−INShi B cells were also sorted and examined. We tested with the 8F10 T cell hybridoma that only recognizes the B:12-20 epitope from pulsing APCs with peptide or denatured insulin but is unreactive to APCs pulsed with insulin (Mohan et al., 2011). The IIT-3 hybridoma specific for the B:13-21 epitope from processing of insulin was tested in parallel (Mohan et al., 2011). Both T cells recognize the B:9-23 peptide that contains both registers.
All of the three B cell subsets pulsed with the B:9-23 peptide robustly stimulated both T cells (Fig. 6 A), indicating their expression of I-Ag7 molecules. Each B cell subset pulsed with insulin activated the IIT-3 T cells, indicating that they generated the stronger MHC-binding B:13-21 epitope during insulin processing (Fig. 6 A). Although the GC−INShi and GC−INSlo B cells pulsed with insulin were unable to stimulate the 8F10 T cells, consistent with our previous experiments (Mohan et al., 2010, 2011), the GC+INS+ B cells activated 8F10 T cells (Fig. 6 A). Notably, when five times more insulin-pulsed non-GC B cells were used to stimulate 8F10 T cells, a weak response was induced by the GC−INSlo but not the GC−INShi B cells (Fig. 6 B).
The findings that the GC+INS+ B cells (gated according to Fig. 6 C) presented the B:12-20 epitope to 8F10 T cells were confirmed in the transfer model (Fig. 6 D). The low recovery of B cells in this model did not permit further fractionation of the GC−INShi and GC−INSlo B cells. Instead, the non–insulin-binding B cells outside GCs (GC−INS−) were analyzed (gated according to Fig. 6 C), and this set was unable to activate 8F10 T cells upon insulin pulse (Fig. 6 D).
These results suggest that B cell activation changes the selection of insulin epitopes. To examine this further, we established a cell culture system in which anti-insulin B cells were treated with various stimuli and then tested with the IIT-3 or 8F10 T cell hybridomas for the response to insulin (Fig. 7, A and B). Because of the difficulties in recovering sufficient anti-insulin B cells from the VH125SD mice, we examined B cells isolated from the 125Tg mice that harbor transgenes expressing the anti-insulin VH125 and Vκ125 chains, giving rise to a monoclonal BCR repertoire in which >98% of B cells were insulin specific (Rojas et al., 2001). Without stimulation, the 125Tg B cells presented insulin to IIT-3 but not 8F10 T cells, indicating that they behaved like unstimulated B cells; that is, capable of presenting the B:13-21 but not the B:12-20 epitope (Fig. 7 A, media). Polyclonal B cells isolated from NOD mice likewise presented insulin to IIT-3 but not to 8F10 T cells (Fig. 7 B, media). The responses in general were considerably weaker than those induced by the 125Tg B cells, signifying a less efficient insulin uptake by WT B cells.
The 125Tg and WT B cells were cultured with the stimuli indicated in Fig. 7 (A and B). 8F10 T cells responded weakly to 125Tg B cells stimulated with soluble CD40 ligand (CD40L) or IL-4 alone, but these two stimuli in combination enabled a strong activation (Fig. 7 A, CD40L + IL-4). Importantly, the cytokine IL-4 was the major molecule ensuring the presentation of the B:12-20 epitope, as indicated by the fact that 125Tg B cells stimulated by LPS combined with IL-4 (LPS + IL-4) but not LPS alone activated 8F10 T cells (Fig. 7 A, bottom). We examined other factors that can be provided by Tfh cells, including the cytokine IL-21 (Linterman et al., 2010; Zotos et al., 2010) and IFN-γ (Reinhardt et al., 2009). Neither of these two cytokines combined with CD40L (CD40L + IL-21 and CD40L + IFN-γ, respectively) further enhanced activation of 8F10 T cells (Fig. 7 A, bottom). Of note, 8F10 T cells responded positively to conventional B cells stimulated by CD40L + IL-4 or LPS + IL-4 at the highest concentration of insulin pulse (Fig. 7 B, bottom). Thus, T cell helper signals, particularly CD40L and IL-4 in synergy, not only function as key mediators regulating GC function but also influence antigen presentation pathways in cognate B cells to ensure optimal and broader T cell–B cell interactions.
There are three relevant findings made here that are important for understanding the pathobiology of autoimmune diabetes. First, class-switched IAAs can originate from dynamic interactions between anti-insulin B cells and a unique set of insulin-reactive T cells that recognize the B:12-20 epitope. Second, the native insulin molecule is being presented and recognized by T and B cells in multiple lymphoid sites, indicating that the islet–pLN axis is not the only location capable of fostering insulin autoreactivity. Third, activated B cells, in particular GC B cells, are able to present a broader repertoire of insulin peptides.
Aberrant Tfh cell responses have been associated with autoimmune diseases, including T1D (Vinuesa et al., 2005; Kenefeck et al., 2015; Ueno et al., 2015). In line with this, we found that 8F10 T cells differentiated into Tfh cells and promoted IAA production. These findings revealed a new layer of the functionality of these T cells and largely explained the origin of class-switched IAAs in autoimmune diabetes. In our previous studies, 8F10 T cells escaped thymic selection and were directly recruited into the islets bypassing the pLN (Mohan et al., 2011, 2013). In this study, we observed 8F10 T cell reactivity in peripheral LNs, pointing to recognition of peptide–MHC complexes. It is possible that this recognition is mediated by a subset of resident APCs that can constitutively present the B:12-20 epitope upon insulin processing or by migratory APCs that are activated in the islets or pLN. The B:12-20 epitope may also be available through the presentation of free insulin peptides by all APC subsets expressing MHCII molecules, although whether insulin peptides can be found in the lymph or blood remains to be determined. Dissecting these events may further reveal how naive 8F10 T cells differentiate into effector or Tfh cells in LNs and whether such processes impose pathogenic outcomes. Above all, 8F10 Tfh cells are competent helper cells, as manifested by their expression of Tfh linage markers and T cell help factors. The result that CD40L in combination with IL-4 allowed optimal presentation of the B:12-20 epitope provided a mechanism by which GC B cells interact with 8F10 T cells. Because CD40L and IL-4 also reversed the anergy of anti-insulin B cells (Acevedo-Suárez et al., 2005), our findings propose a model in which signaling events relevant to T cell help, tolerance breakdown, and altered antigen presentation pathways are integrated to ensure anti-insulin GC responses. The mode of action of CD40L plus IL-4, such as regulation of H2-DM and H2-DO expression, is a subject of intense research at present.
The finding of systemic immunoreactivity to insulin indicates that the low concentration (∼100 pM) of circulating insulin is sufficient to support GC reactions, even in the spleen, an organ lacking lymphatics. Insulin is also found in lymph (Rasio et al., 1967; Yang et al., 1989) and may enter LNs into the subcapsular sinus to make it available to anti-insulin B cells in the follicles, like other small soluble proteins (Gretz et al., 2000; Pape et al., 2007; Batista and Harwood, 2009; Roozendaal et al., 2009). Therefore, in these instances, spontaneous GC formation may be dependent on persistent availability of a self-antigen rather than on a high concentration. The finding of insulin presentation throughout the lymphoid system should be extrapolated to other endocrine autoimmune diseases in which hormones are the target antigen. The systemic presentation of the hormone could be relevant in two contexts, as in here, where strong CD4 T cell autoreactivity results in B cell activation and autoantibody formation. But also such presentation may be modulatory and may control the activation of both T and B cells (Goodnow et al., 1988; Adelstein et al., 1991; Cooke et al., 1994; Rojas et al., 2001; Acevedo-Suárez et al., 2005; Henry et al., 2009; Zikherman et al., 2012; Kendall et al., 2013).
On the cellular basis, cognate T cell–B cell interactions are required for anti-insulin GC formation. It has been suggested that T cell help is a critical limiting factor for GC selection (Victora et al., 2010) and that GC B cells presenting high amounts of antigens are selectively expanded by Tfh cells (Gitlin et al., 2014). Our results reinforced this notion by showing that the GC+INS+ cells actively presented the unconventional B:12-20 epitope, which likely ensured optimal interactions with 8F10 Tfh cells. Beyond efficient antigen presentation by GC B cells (Glazier et al., 2002), our finding further revealed that epitope selection by GC B cells is less constrained, allowing presentation of a broader repertoire of peptides. On the other hand, cellular events concerning how anti-insulin B cells are initially selected into GCs are less understood. We detected a weak presentation of the B:12-20 epitope by the GC−INSlo but not the GC−INShi B cells. We speculate that this weak response may come from rare B cells making initial contact with 8F10 T cells before the GC phase, an event that may occur at the border of the T cell–B cell zone (Okada and Cyster, 2006). This idea is supported by previous data showing that the GC−INSlo B cells were functionally more activated than the GC−INShi B cells (Kendall et al., 2007; Henry-Bonami et al., 2013) and that activation of anti-insulin B cells enabled presentation of the B:12-20 epitope.
The cooperativity between anti-insulin T and B cells in exacerbation of diabetes transfer is relevant to the role of B cells in T1D development. Previous studies have shown arrested diabetes progression in the B cell–deficient (µMT−/−) NOD mice (Serreze et al., 1996; Akashi et al., 1997). In general, B cells may contribute to T1D development by functioning as APCs and/or producing anti-islet antibodies. Supporting a role of APCs, impaired effector functions of CD4 and CD8 T cells were observed in µMT−/− mice (Greeley et al., 2001; Mariño et al., 2012) and in mice with B cell depletion (Hu et al., 2007). Moreover, ablation of I-Ag7 in B cells significantly reduced diabetes incidence and insulitis severity (Noorchashm et al., 1999). Given that these manipulations also abolished antibody production, a role of antibody in these models was not excluded. In fact, anti–hen egg lysozyme (HEL) antibodies were able to assist HEL-reactive T cells to trigger diabetes in mice expressing HEL in the islets (Silva et al., 2011). In another study, diabetic autoimmunity was ensured through cooperation between anti-OVA antibodies and OVA-specific CD8 T cells (Harbers et al., 2007). In our model, IAA production is observed concomitantly with exacerbated diabetes development, implying a role of IAAs in assisting T cell responses. Whether IAAs are able to target the islet and directly participate in diabetogenesis through mechanisms involving complement and Fc-γ receptors (Harbers et al., 2007) requires further investigation.
MATERIALS AND METHODS
NOD/ShiLtJ (NOD), NOD.129S7(B6)-Rag1tm1Mom/J (NOD.Rag1−/−), and NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/DoiJ (BDC 2.5) mice were obtained from The Jackson Laboratory.
The 125Tg mice (on the NOD background) expressing anti-insulin BCR heavy and light chain transgenes were described previously (Rojas et al., 2001). The VH125SD mice that harbor an anti-insulin BCR heavy chain site directed to native IgH locus on the C57BL/6 background (Williams et al., 2015) were backcrossed onto the NOD background for >10 generations. The 8F10 TCR transgenic mice specific for the 12–20 fragment of the insulin B chain (VEALYLVCG; Mohan et al., 2013) were crossed with the VH125SD mice to generate the 8F10-VH125SD double transgenic mice. Flow cytometry analyses confirmed that >95% of B cells in the VH125SD and 8F10-VH125SD mice were transgenic (IgMa+). The 8F10.Rag1−/− mice were generated by intercrossing the 8F10 mice with the NOD.Rag1−/− mice. All the mice were maintained in specific pathogen-free conditions, and all animal studies were approved by the Division of Comparative Medicine of the Washington University School of Medicine.
The following antibodies were purchased from BioLegend: PerCP-Cy5.5 anti-B220 (RA3-6B2), PE anti-CD103 (2E7), APC-Cy7 anti-CD11c (N418), PE-Cy7 anti-CD4 (RM4-5), BV510 anti-CD45 (30-F11), PerCP-Cy5.5 anti-CD8a (53-6.7), APC anti-F4/80 (BM8), APC anti-CXCR5 (L138D7), Brilliant violet 421 anti-PD1 (29F.1A12), FITC anti-IgMb (AF6-78), PE anti-IgMa (MA-69), and FITC anti-Vβ8.1/8.2 (KJ16-133.18). The following antibodies were purchased from eBioscience: Alexa Fluor 488 anti-GL7 (GL7), PE-Cy7 anti-IgD (11-26), PerCP-eFluor 710 anti-Fas (15A7), PE or eFluor 450 anti-CD19 (1D3), APC anti-CD25 (PC61.5), FITC anti-CD44 (IM7), and PE anti-FoxP3 (FJK-16s). The following antibodies were purchased from BD: PE anti-CD62 ligand (MEL-14), FITC or APC anti-CD3e (145-2C11), and FITC anti-Vβ4 (KT4). APC-conjugated F(ab′)2 donkey anti–mouse IgG (H+L) was purchased from Jackson ImmunoResearch Laboratories, Inc., and Pacific blue I-Ag7 (AG2.42.7) was made in our laboratory.
Flow cytometry and cell sorting
Single-cell suspensions were treated with FcR-blocking media containing 2.4G2 antibodies. The cells were then stained with fluorescent antibodies on ice for 25 min followed by incubation with cell viability dye (eBioscience). For detection of insulin-binding B cells, cells were incubated with 50 ng/ml biotinylated insulin (Eagle Biosciences) with or without inhibition with 500 ng/ml unconjugated insulin for 30 min on ice followed by staining with APC-conjugated streptavidin (BioLegend) for 15 min. The FoxP3 staining was performed using a transcription factor buffer set (eBioscience). The flow cytometry samples were collected using a FACSCanto II (BD), and data were analyzed using FlowJo software (Tree Star). Cell sorting was performed using a FACSAria II (BD).
The duodenum ampulla was clamped, and the pancreas was perfused with 5-ml calcium-free Hank’s balanced salt solution supplemented with 0.4 mg/ml type XI collagenase (Sigma-Aldrich) through the common bile duct. The pancreases were then removed and digested for 15 min at 37°C. After a 90-s shaking, the digestion mixture was washed and passed through a 70-µm cell strainer. The islet-containing fraction retained by the strainer was flushed and stained with 200 mg/ml of the zinc-chelating dye dithizone (Sigma-Aldrich) as a marker of islets. The islets were then handpicked and dispersed in Cell Dissociation Solution Non-Enzymatic (Sigma-Aldrich) for 3 min at 37°C for single-cell suspensions.
4-wk-old female 8F10-VH125SD mice were injected with anti-CD25 (PC61) antibody or the isotype control Rat IgG i.p. on day 0, 3, 6, and 9 (500 µg per injection). The mice were monitored for diabetes development for another 30 d.
IAA measurement by ELISA
96-well ELISA plates were coated with 1 µg/well of human insulin (Sigma-Aldrich) overnight at 4°C and were blocked with 3% BSA in PBS. Sera were divided into two equal aliquots that were incubated with or without 10 µg/ml insulin on ice for 1 h. The sera were then added to insulin-coated plates for incubation overnight at 4°C. After extensive washes, the plates were incubated with HRP-conjugated goat anti–mouse IgG1, IgG2a, and IgG2b antibodies (1:10,000; Jackson ImmunoResearch Laboratories, Inc.) for 1 h at room temperature. The enzyme reactions were probed by the OptEIA TMB Substrate Reagent Set (BD), and the data were collected using an iMark Microplate Reader (Bio-Rad Laboratories).
B cell stimulation
125Tg and WT B cells were isolated from spleens by negative selection using magnetic beads (Miltenyi Biotech) with a purity of ≥95%. The cells were plated in V-bottom 96-well plates (105 per well) and were cultured with various stimuli, including 500 ng/ml of soluble CD40 ligand (eBioscience), 1 µg/ml LPS (Sigma-Aldrich), and 50 ng/ml recombinant murine IL-4, IL-21, and IFN-γ (PeproTech). After incubation for 18 h, the plates were washed with cold media three times, and the B cells were used for antigen presentation assays.
Antigen presentation assay
FACS-sorted GC and non-GC B cells (2 × 104 per well in Fig. 6 [A and D] and 105 per well in Fig. 6 B) were cultured with T cell hybridomas in the presence of 50 µM insulin or 10 µM of the B:9-23 peptide (SHLVEALYLVCGERG). In Fig. 7 (A and B), 125Tg and WT B cells (5 × 104 per well) were cultured with T cell hybridomas in the presence of serially diluted insulin. In all of the assays, T cell hybridomas (5 × 104 per well) were cultured with APCs in round-bottom 96-well plates. After incubation for 18 h, the culture supernatant from each well was collected and used to culture the IL-2–dependent cell line CTLL-2 (104 per well). The proliferation of CTLL-2 cells was assessed by [3H]thymidine incorporation.
Adoptive transfer and diabetes monitoring
FACS-sorted naive T cells (CD4+CD8−B220−CD25−CD62LhiCD44−) from 8F10.Rag1−/− or BDC2.5 mice were transferred i.v. into 4–8-wk-old NOD.Rag1−/− recipients (2 × 105 per mouse). In some experiments, the T cells were cotransferred with 2 × 106 FACS-sorted B cells (CD19+CD4−CD8−IgMa+GL7−IgG−) from VH125SD or WT NOD mice. Blood glucose was monitored daily or weekly (Chemstrip 2GP; Roche), and the mice were considered diabetic with a blood glucose level of ≥250 mg/dl for two consecutive measurements.
RNA isolation and quantitative RT-PCR
Total RNA was isolated from FACS-sorted naive and Tfh cells using the Ambion RNAqueous-Micro kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. The cDNA was generated using the iScript Reverse Transcription Supermix (Bio-Rad Laboratories). Quantitative RT-PCR was performed using the PerfeCTa SYBR green Fast Mix (Quanta Biosciences) on a StepOnePlus Real-Time PCR system running StepOne software.
The log-rank (Mantel-Cox) test was used to determine significant differences in diabetes incidence. The Mann-Whitney U test was used to determine significant differences between individual biological replicate samples. The paired Student’s t test was used to calculate p-values of each paired independent experiment with pooled mice.
We thank members of the Unanue laboratory for advice on various aspects of the project. Katherine Fredericks, Rachel Bonami, Kelly Hainz, Chrys Hulbert, and Lindsey Moore helped us on various technical aspects.
Our work was supported by National Institutes of Health grants DK058177, DK020579, AI051448, and R21 DK091692 as well as by the Juvenile Diabetes Research Foundation (SRA-2014-293).
The authors declare no competing financial interests.
- Abbreviations used:
- axillary LN
- germinal center
- hen egg lysozyme
- insulin autoantibody
- inguinal LN
- mesenteric LN
- non-obese diabetic
- pancreatic LN
- type 1 diabetes
- Submitted: 29 November 2015
- Accepted: 9 March 2016
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).